Anticipate generic drug launch
Manage your formulary budget
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Find generic entry opportunities
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Transdermal therapeutic system comprising as active component buprenorphine|
|Abstract:||The controlled release of buprenorphine or the pharmaceutically acceptable salts thereof to the skin over a period of time of at least 24 hours is ensured by a transdermal therapeutic system consisting of a backing layer which is impermeable to the active substance, a pressure-sensitive adhesive reservoir layer, and optionally a removable protective layer. Said reservoir layer of said system comprises 20 to 90%-wt polymeric material, 0.1 to 30%-wt softener, 0.1 to 20%-wt buprenorphine base or one of the pharmaceutically acceptable salts thereof, and 0.1 to 30%-wt solvent for the active substance base.|
|Inventor(s):||Hille; Thomas (Neuwied, DE), Deurer; Lothar (Koblenz, DE), Hoffmann; Hans-Rainer (Neuwied, DE)|
|Assignee:||LTS Lohmann Therapie-Systeme GmbH & Co. KG (Neuwied, DE)|
Patent Claim Types:|
see list of patent claims
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Germany||3939376||Nov 29, 1989|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Austria||135205||<disabled in preview>|
|Australia||632182||<disabled in preview>|
|Australia||6569990||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.